Navigation Links
Immuno-Oncology 360° (IO360°) NYC Gathering Announces Keynotes for the 5th Annual Event

The Conference Forum announces the keynote-speaking faculty for the 5th annual Immuno-Oncology 360° summit to be held February 6-8, 2019 at the Crowne Plaza Times Square in New York City.

The opening keynote of the Translational Science and Emerging Biomarker plenary session is Genentech’s Global Franchise Leader in Cancer Immunotherapy Biomarkers and IO360° Plenary Chair, Priti Hegde, PhD. Dr Hegde will address biomarker signaling and turning cold tumors hot.

IO clinical trial pioneer, Founder and Co-Principal Investigator of I-SPY 2 and Director, Carol Franc Buck Breast Cancer Center at UCSF, Dr Laura Esserman will provide the plenary keynote for the Clinical Trial Operations in IO session on day two of the IO360° summit. Dr Esserman will share the remarkable progress achieved by the I-SPY 2 clinical trials in improving breast cancer outcomes. Dr Esserman will also share how the innovative clinical trial model is impacting beyond breast cancer by increasing efficiencies and accelerate the development of more effective therapies for a wider range of cancers and other diseases.

The most prestigious analyst in IO, Andrew Baum, MD, Head of Global Healthcare and Managing Director, Equity Research for Citi will lead the Financial and Commercial Implications plenary session. Dr Baum along with IPO experts David Epstein, MBA, Executive Partner, Flagship Pioneering and Dan Passeri, JD, President and CEO of Cue Biopharma will join forces on a panel title “Turning an Asset into Value” to share what goes into preparing for an IPO, straight licensing with the transition to a public company and decision making on prioritization within portfolios.

IO360° introduces a new plenary session on Next Generation Cell Therapy, which features talks on optimization through engineering t-cells led by the University of Pennsylvania and emerging cell therapy approaches led by GSK and Janssen Oncology.

New leadership to IO360° include: Ronald Herbst, PhD, Medimmune; Cedrik Britten, MD, GSK; Theresa LaVallee, PhD, Parker Institute for Cancer Immunotherapy; Tara Arvedson, PhD, Amgen; Jonathan Zalevsky, PhD, Nektar; Tahamtan Ahmadi, MD, PhD, GenMab; Adriana Comprelli, BMS; Aung Naing, MD, FACP, MD Anderson Cancer Center; Martin Oft, MD, ARMO; Ian Pyrah, PhD, Seattle Genetics; Marco Ruella, MD, University of Pennsylvania; Lawrence Schwartz, MD, Columbia University Medical Center; Andrea van Elsas, PhD, ADURO; Stephen Willingham, PhD, Corvus Pharmaceuticals; Anton Xavier, MBA, NYS Center for Biotechnology and Sadik Kassim, PhD, Mustang Bio; Matthew Mulvey, PhD, BeneVir.

Drug development mavericks, Roy Baynes, MD, PhD, Merck, Daniel Chen, MD, PhD, IGM Biosciences (formerly of Genentech) and Michael Kalos, PhD, Janssen (formerly of Eli Lilly) are back with provide updates on clinical developments including new cell therapy approaches and a deeper look at biomarkers and companion diagnostics for predicting response.

IO360° is divided into the following plenaries with data presentations and panel discussions on Discovery and Preclinical Science, Translational Science, Biomarkers and Diagnostics, Clinical Operations and Development, Next Generation Cell Therapy, Imaging Aspects, Business Developments, Financial and Commercial Implications, Emerging Technologies, and Trends in the Field.

“It is a privilege and honor to work with all stakeholders from pharma, biotech, academia, investors, FDA and patients to foster collaborations that lead to significant advances in Immuno-Oncology through IO360°,” says Conference Director Kate Woda.

IO360° will also feature extensive networking opportunities and includes a one-on-one partnering system to help facilitate business meetings and additional collaborations.

About Immuno-Oncology 360°:
Immuno-Oncology (IO) 360° is the premier meeting across all stakeholders in IO, addressing the rapid advancements of clinical, scientific and business developments of IO in one setting to help develop therapeutics for a wider range of cancers at an accelerated rate. Guided by lead advisors Axel Hoos, MD, PhD, SVP of Oncology R&D, GSK, James Gulley, MD, PhD, Head of Immunotherapy Section and Director of Medical Oncology Service at the Office of the Clinical Director, Center for Cancer Research, NCI and Andrew Baum, MD, Head of Global Healthcare and Managing Director, Equity Research, Citi, the three-day summit features ten plenary sessions with over 80 speakers and includes ten plus hours of networking. There will be over 450 attendees representing pharma, biotechs, academia, research organizations, business development and the investment community focused on IO.

About the Conference Forum
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, exchange of ideas and solutions among peers, as well as providing high quality networking.

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology news :

1. ACEA Biosciences Launches xCELLigence® RTCA Software Pro to Further Enhance Immuno-Oncology Experimental Design and Analysis
2. Gathering information about food is not top priority for individuals with high metabolisms
3. Gathering the clues to rare gene variants contributing to schizophrenia
4. Merck Animal Health announces Vetsulin
5. AAPS announces 2013 National Biotechnology Conference award winners
6. PLOS announces Accelerating Science Award Program
7. DFG announces recipients of 2013 Heinz Maier-Leibnitz Prize
8. Missouri Botanical Garden program announces collaboration with LHerboretum
9. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
10. Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics
11. DigitalPersona Announces U.are.U Software Development Kit (SDK) for Android Applications
Post Your Comments:
(Date:5/21/2019)... ... ... The ASGCT Clinical Trials Finder is a customizable search engine for ... curated daily from ensures the most up-to-date and applicable listings anywhere in the ... the development of the ASGCT Clinical Trials Finder reviewed the relevance of ...
(Date:5/16/2019)... ... May 16, 2019 , ... SFC Fluidics, Inc. ... the Industry Development and Discovery Partnership that was awarded to SFC Fluidics in 2018 ... integrated pod artificial pancreas (AP) system for people with type 1 diabetes (T1D). By ...
(Date:5/14/2019)... ISLAND, N.Y. (PRWEB) , ... May 13, 2019 ... ... will be participating in the BIOMEDevice Expo in Boston on May 15-16, 2019, ... the medical technology industry including, MedTech, design engineering, and embedded systems product organizations. ...
Breaking Biology News(10 mins):
(Date:4/25/2019)... ... April 24, 2019 , ... Inference Solutions ... service organizations, today announced global availability of Inference Studio’s latest version, which makes ... sizes to harness the power of Google’s Contact Center AI (CCAI). ...
(Date:4/15/2019)... ... April 15, 2019 , ... Sirrus, ... a $2 million bench plant expansion to increase production of methylene malonate monomers ... design and construction of Sirrus’ full-scale production facility, which is scheduled to break ...
(Date:4/9/2019)... ... 09, 2019 , ... USDM Life Sciences , the ... organizations to accelerate innovation and maximize productivity, announces that nearly 100 companies have ... , USDM’s Cloud Assurance is a managed subscription service delivering end-to-end ...
(Date:4/8/2019)... ... April 08, 2019 , ... US Capital Global ... $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”). ... Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to begin ...
Breaking Biology Technology: